Ludwig Cancer Research and Cancer Research Institute Partner with Targovax to Test Candidate Virotherapy in Early-Phase Clinical Trials
Thursday, November 19, 2015 - 05:13
in Health & Medicine
Ludwig Cancer Research and the Cancer Research Institute (CRI) announced today an agreement with the biotechnology company Targovax to evaluate its experimental virotherapy, ONCOS-102, in early phase clinical trials testing the virotherapy in combination with other, potentially synergistic immunotherapies such as checkpoint inhibitors.